^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NTX-301

    i
    Other names: NTX-301, AST-081, XNTR-20-02
    Company:
    Aston Sci., Korea University, PinotBio
    Drug class:
    DNMT inhibitor
    Related drugs:
    1year
    Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML (ASH 2023)
    Additionally, NTX-301 treatment increased caspase-8 and cleaved-caspase-8 in AML cells independent of TP53 mutation status, consistence with reports showing caspase-8 hypermethylation in AML and supporting that activation of caspase-8-mediated extrinsic apoptosis as a mechanism of NTX-301 action. In conclusion, our data suggest that NTX-301 has more potent anti-leukemia activities compared to current HMA in clinic and synergizes with venetoclax in venetoclax-resistance and TP53-mutant AML and AML stem/progenitor cells, and warrants clinical evaluation
    IO biomarker
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • MCL1 (Myeloid cell leukemia 1) • MDM2 (E3 ubiquitin protein ligase) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • DNMT1 (DNA methyltransferase 1) • CASP8 (Caspase 8)
    |
    TP53 mutation • TP53 wild-type • MCL1 overexpression • MCL1 expression • MDM2 mutation • TP53 mutation + MDM2 mutation
    |
    Venclexta (venetoclax) • NTX-301